The safety of finasteride used in benign prostatic hypertrophy: A non-interventional observational cohort study in 14 772 patients

British Journal of Urology

Volumn 78, Issue 3, 1996, Pages 379-384

  Wilton, L ^a   Pearce, G ^a   Edet, E ^a   Freemantle, S ^a   Stephens, M D B ^a   Mann, R D ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

Benign prostatic hypertrophy; Drug safety; Finasteride; Gynaecomastia; Post marketing surveillance; Prescriptionevent monitoring; Sexual dysfunction

Indexed keywords

AMLODIPINE; BETAXOLOL; CISAPRIDE; DILTIAZEM; DOXAZOSIN; ENALAPRIL; FAMOTIDINE; FINASTERIDE; LISINOPRIL; MISOPROSTOL; NEDOCROMIL; NICARDIPINE; NIZATIDINE; OMEPRAZOLE; SALMETEROL; SERTRALINE; XAMOTEROL; ZOPICLONE;

AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EJACULATION; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO; MAJOR CLINICAL STUDY; MALE; OBSERVATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; EJACULATION; ENZYME INHIBITORS; FINASTERIDE; GYNECOMASTIA; HAIR DISEASES; HUMANS; IMPOTENCE; LIBIDO; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSTATIC HYPERPLASIA; URINATION DISORDERS;

EID: 0030423280     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.00091.x     Document Type: Article

References (9)

1. Rawlins MD, Jefferys DB. United Kingdom Product Licence applications involving new active substances, 1987-1989: their fate after appeals. Br J Clin Pharmacol 1993; 35: 599-602
2. Inman WHW, Kubota K, Pearce GL, Wilton LV. PEM Report No. 10, Zopiclone. Pharmacoepidemiology and Drug Safety 1993; 2: 499-521
3. Mann RD, Kubota K, Pearce GL, Wilton LV. Salmeterol: a study of Prescription-Event Monitoring in a cohort of 15,407 patients. J Clin Epidemiol 1996; 49: 247-50
4. Wilton LV, Pearce GL. Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. BrJCIin Pharmacol 1996; 41: 277-84
5. Rawson NSB. An acute adverse drug reaction alerting scheme using the Saskatchewan health datafiles. Drug Invest 1993; 6: 245-56
6. Johnson NL, Kotz S. Poisson distribution. In Johnson NL, Kotz S eds, Discrete Distributions, Boston: Houghton Mifflin Co., 1969: 87-121
7. Kubota K, Kubota N, Pearce GL, Prescott P, Mann RD. Signalling drug-induced rash with 36 drugs recently marketed in the United Kingdom and studied by PrescriptionEvent Monitoring. Int J Clin Pharmacol Therap 1995; 33: 219-25
8. Andrew JE, Prescott P, Smith IMF, Inman WHW, Kubota K. Testing for adverse reactions using Prescription-Event Monitoring. Statistics in Medicine 1996; 15: 987-1002
9. Edwards IR, Lindguist M, Wiholm BE, Napke E. Quality criteria for early signals for possible adverse drug reactions. Lancet 1990; 336: 156-8